CN115531601B - 一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料及其制备方法 - Google Patents
一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料及其制备方法 Download PDFInfo
- Publication number
- CN115531601B CN115531601B CN202211144227.4A CN202211144227A CN115531601B CN 115531601 B CN115531601 B CN 115531601B CN 202211144227 A CN202211144227 A CN 202211144227A CN 115531601 B CN115531601 B CN 115531601B
- Authority
- CN
- China
- Prior art keywords
- percent
- skin
- hydrogel dressing
- solution
- inflammatory response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 27
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 22
- 230000028709 inflammatory response Effects 0.000 title claims abstract description 18
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 206010061218 Inflammation Diseases 0.000 claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 claims abstract description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 14
- 229920001184 polypeptide Polymers 0.000 claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 10
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 8
- 239000000679 carrageenan Substances 0.000 claims abstract description 8
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 8
- 229920001525 carrageenan Polymers 0.000 claims abstract description 8
- 229940113118 carrageenan Drugs 0.000 claims abstract description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 8
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 8
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims abstract description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 7
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims abstract description 7
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims abstract description 7
- 229960002216 methylparaben Drugs 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 238000001126 phototherapy Methods 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 108010058643 Fungal Proteins Proteins 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims description 2
- 239000003531 protein hydrolysate Substances 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 abstract description 8
- 208000002193 Pain Diseases 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000036407 pain Effects 0.000 abstract description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 4
- 230000019612 pigmentation Effects 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 2
- 230000003467 diminishing effect Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009692 water atomization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料及其制备方法，属于水凝胶敷料领域。本发明所述水凝胶敷料以质量百分数计，包括以下原料：海藻糖0.2‑2.0％、卡拉胶0.5‑5.0％、乙二胺四乙酸二钠0.1‑1.0％、甘油1.0‑5.0％、甘草酸二钾0.1‑1.0％、酵母多肽类1.0‑5.0％、对羟基苯甲酸甲酯0.1‑0.5％，余量为纯水。本发明水凝胶敷料可有效控制皮肤光电治疗的术后反应，快速收缩毛细血管，减轻水肿与渗出，缓解红肿热痛，并具有抑菌、消炎、止痒、预防色素沉着等作用。
Description
技术领域
本发明涉及水凝胶敷料技术领域，尤其涉及一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料及其制备方法。
背景技术
皮肤光电治疗是现代医疗美容领域最常见的治疗手段，通过激光、射频等物理能量作用于相应的皮肤组织，对治疗痤疮、色素性皮肤病、血管性皮肤病以及维持皮肤年轻化等具有确切的疗效。但与此伴随的，必然有一定程度的治疗术后炎症反应，普遍表现为红、肿、热、痛、干、痒等症状，有的还有少量出血、色素沉着等，给患者的身心都造成较大的痛苦。现有的应对办法主要是采用冰敷(冰袋冷敷)、冷喷(冷水雾化)或贴敷医用面膜，但是上述方法基本都是围绕吸收创面渗液、抗感染、提供湿性环境等为促进创面愈合而展开，既不方便，效果也很有限。目前尚没有专门针对光电治疗术后炎症反应而设计开发的产品。因此，光电治疗术后的炎症反应处理，是临床上亟待解决的现实问题。
发明内容
有鉴于此，本发明提供了一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料及其制备方法，本发明提供的水凝胶敷料可有效控制皮肤光电治疗的术后反应，快速收缩毛细血管，减轻水肿与渗出，缓解红肿热痛，并具有抑菌、消炎、止痒、预防色素沉着等作用。
本发明的第一个目的在于提供一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料，以质量百分数计，包括下述原料：海藻糖0.2-2.0％、卡拉胶0.5-5.0％、乙二胺四乙酸二钠0.1-1.0％、甘油1.0-5.0％、甘草酸二钾0.1-1.0％、酵母多肽类 1.0-5.0％、对羟基苯甲酸甲酯0.1-0.5％，余量为纯水。
优选的，所述酵母多肽类包括但不限于来自酿酒酵母、啤酒酵母、面包酵母、酵母抽提物等至少一种酵母蛋白水解或酶解物。
本发明的第二个目的在于提供所述缓解皮肤光电治疗术后炎症反应的水凝胶敷料的制备方法，包括以下步骤：
(1)将甘油、甘草酸二钾、对羟基苯甲酸甲酯、乙二胺四乙酸二钠溶解在纯水中，得到溶液A；
(2)然后在步骤(1)所述的A溶液中加入卡拉胶和海藻糖，搅拌溶解完全后，得到溶液B；
(3)在步骤(2)所述B溶液中加入酵母多肽类，搅拌溶解20min，得到溶液C；
(4)将步骤(3)所述溶液C降低温度后浇注在模型中，依次经冷却、成型、装袋和抽真空封口，得到缓解皮肤光电治疗术后炎症反应的水凝胶敷料。
优选的，步骤(1)所述溶解的温度为35-45℃。
优选的，步骤(2)所述溶解的温度为45-55℃。
优选的，步骤(3)所述溶解的温度为60-80℃，进一步优选的，所述溶解的温度为70℃。
优选的，步骤(4)所述温度为45-55℃。
本发明的第三个目的在于提供一种如上所述缓解皮肤光电治疗术后炎症反应的水凝胶敷料或如上所述的制备方法制备的水凝胶敷料在制备缓解皮肤光电治疗术后炎症反应的药物中的应用。
与现有技术相比，本发明具有以下有益效果：
本发明制备的缓解皮肤光电治疗术后炎症反应的水凝胶敷料是以卡拉胶和海藻糖为主体的水凝胶体，可以形成具有强大持水能力的三维网状结构，该三维网状结构能平稳的释放所负载的功效成分。本申请制备的缓解皮肤光电治疗术后炎症反应的水凝胶敷料中的精选功效成分为甘草酸二钾和酵母多肽，其中甘草酸二钾通过抑制前列腺素E2(PGE2)的产生、抑制透明质酸酶活性、抑制酪氨酸酶的生成和激活，实现抗炎、止痒、防色沉的效果；酵母多肽为由不同数量氨基酸组成的多肽类，具有调节皮肤免疫功能、促进新陈代谢，促进水通道蛋白酶的合成，刺激细胞再生，增殖新生胶原等效果，配合甘草酸二钾使用，能够较好的控制术后炎症反应，保持皮肤的含水量。三维网状结构中，高含量的适当温度(不是冰)的水份，可在维持胶原热效应的前提下使皮肤局部降温，终止光电热力对皮肤的继续损伤，提高光电治疗的效果。本发明制备的缓解皮肤光电治疗术后炎症反应的水凝胶敷料在所选原料之间的协同作用下，可达到有效控制皮肤光电治疗的术后反应，快速收缩毛细血管，减轻水肿与渗出，缓解红肿热痛的效果，此外还具有抑菌、消炎、止痒、预防色素沉着等作用。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚，下面将对本发明的技术方案进行清楚、完整的描述。显然，所描述的实施例仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施例，都属于本发明所保护的范围。
下述实施例中所述试验方法或测试方法，如无特殊说明，均为常规方法；所述原料和助剂，如无特殊说明，均从常规商业途径获得，或以常规方法制备。
实施例1
一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料的制备方法，具体步骤如下：
(1)称取40g甘油、5g甘草酸二钾、2g对羟基苯甲酸甲酯、3g乙二胺四乙酸二钠溶解在900ml纯水中，在40℃的温度下搅拌溶解，得到溶液A；
(2)然后在步骤(1)所述的A溶液中加入15g卡拉胶和5g海藻糖，在45℃的温度下搅拌，待溶解完全后，得到溶液B；
(3)在步骤(2)所述B溶液中加入40g酵母多肽类，在70℃的温度下搅拌20min，得到溶液C；
(4)将步骤(3)所述溶液C降温至55℃后，浇注在塑料基衬模型中，依次经冷却、成型、装袋和抽真空封口，得到缓解皮肤光电治疗术后炎症反应的水凝胶敷料。
实施例2
一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料的制备方法，具体步骤如下：
(1)称取50g甘油、15g甘草酸二钾、5g对羟基苯甲酸甲酯、5g乙二胺四乙酸二钠溶解在1900ml纯水中，在45℃的温度下搅拌溶解，得到溶液A；
(2)然后在步骤(1)所述的A溶液中加入20g卡拉胶和20g海藻糖，在 45℃的温度下搅拌，待溶解完全后，得到溶液B；
(3)在步骤(2)所述B溶液中加入50g酵母多肽类，在70℃的温度下搅拌20min，得到溶液C；
(4)将步骤(3)所述溶液C降温至50℃后，浇注在塑料基衬模型中，依次经冷却、成型、装袋和抽真空封口，得到缓解皮肤光电治疗术后炎症反应的水凝胶敷料。
对比例1
对比例1采用传统医用透明质酸敷贴。
性能评价：
选取20名进行过皮肤光电治疗术的志愿者，将志愿者随机分为2组，实验组10名术后即刻使用本发明实施例1制备的产品，对照组10名，术后即刻使用本发明对比例1提供的医用透明质酸敷贴，实验组和对照组除了使用的产品不同，其余测试条件一致。经效果对比可知，相比于对比例1使用传统医用面膜，本发明实施例1制备的产品可显著缩短术后炎症反应持续时间。
皮肤光电治疗术后不同时间炎症反应评分比较结果如下表：
| 时间(h) | 0(术后即刻) | 0.5 | 1 | 2 | 4 | 8 | 24 |
| 实验组 | 28 | 21 | 10 | 5 | 2 | 1 | 0 |
| 对照组 | 27 | 25 | 23 | 20 | 14 | 10 | 6 |
皮肤光电治疗术后炎症反应评分记录表结果如下：
注：术后炎症反应评分标准：观察治疗部位的红斑、水肿及灼热等急性炎症反应症状进行等级判定和评分。0分:无红斑、水肿、灼热；1分:红斑明显，水肿和灼热较轻；2分:红斑及灼热明显，水肿较轻，有轻微的灼痛；3分: 红斑、水肿及灼热、灼痛及点状渗血均明显。
参考文献：潘永正，吴迪，张敬东，等.透明质酸敷料用于面部超脉冲CO2 点阵激光术后的临床观察[J].中国激光医学杂志，2014，23(2):90-93， 114.
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (2)
1.一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料，其特征在于，以质量百分数计，包括下述原料：海藻糖0.2-2.0％、卡拉胶0.5-5.0％、乙二胺四乙酸二钠0.1-1.0％、甘油1.0-5.0％、甘草酸二钾0.1-1.0％、酵母多肽1.0-5.0％、对羟基苯甲酸甲酯0.1-0.5％，余量为纯水；所述酵母多肽来自啤酒酵母、面包酵母至少一种酵母蛋白水解或酶解物；
所述的缓解皮肤光电治疗术后炎症反应的水凝胶敷料的制备方法，包括以下步骤：
(1)将甘油、甘草酸二钾、对羟基苯甲酸甲酯、乙二胺四乙酸二钠溶解在纯水中，得到溶液A；
(2)然后在步骤(1)所述的溶液A中加入卡拉胶和海藻糖，搅拌溶解完全后，得到溶液B；
(3)在步骤(2)所述溶液B中加入酵母多肽，搅拌溶解20min，得到溶液C；
(4)将步骤(3)所述溶液C降低温度后浇注在模型中，依次经冷却、成型、装袋和抽真空封口，得到缓解皮肤光电治疗术后炎症反应的水凝胶敷料；
步骤(1)所述溶解的温度为35-45℃；
步骤(2)所述溶解的温度为45-55℃；
步骤(3)所述溶解的温度为60-80℃；
步骤(4)所述温度为45-55℃。
2.根据权利要求1所述缓解皮肤光电治疗术后炎症反应的水凝胶敷料在制备缓解皮肤光电治疗术后炎症反应的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211144227.4A CN115531601B (zh) | 2022-09-20 | 2022-09-20 | 一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211144227.4A CN115531601B (zh) | 2022-09-20 | 2022-09-20 | 一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115531601A CN115531601A (zh) | 2022-12-30 |
| CN115531601B true CN115531601B (zh) | 2024-05-03 |
Family
ID=84728212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211144227.4A Active CN115531601B (zh) | 2022-09-20 | 2022-09-20 | 一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115531601B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103002870A (zh) * | 2010-07-22 | 2013-03-27 | 宝洁公司 | 利用糖海带提取物改善色素沉着斑点外观的方法 |
| CN111658818A (zh) * | 2020-06-23 | 2020-09-15 | 湖南美媛本草生物工程有限公司 | 一种医用修复敷料及其应用 |
| CN113616850A (zh) * | 2021-09-02 | 2021-11-09 | 长春工业大学 | 一种高透明皮肤修复水凝胶敷料及其制备方法 |
| CN113648260A (zh) * | 2021-09-26 | 2021-11-16 | 广东瀚森生物科技有限公司 | 一种酵母修复微精华及其制备方法 |
| CN114469822A (zh) * | 2020-10-23 | 2022-05-13 | 广州樱奈儿化妆品有限公司 | 一种祛痘修护霜及其制备方法 |
-
2022
- 2022-09-20 CN CN202211144227.4A patent/CN115531601B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103002870A (zh) * | 2010-07-22 | 2013-03-27 | 宝洁公司 | 利用糖海带提取物改善色素沉着斑点外观的方法 |
| CN111658818A (zh) * | 2020-06-23 | 2020-09-15 | 湖南美媛本草生物工程有限公司 | 一种医用修复敷料及其应用 |
| CN114469822A (zh) * | 2020-10-23 | 2022-05-13 | 广州樱奈儿化妆品有限公司 | 一种祛痘修护霜及其制备方法 |
| CN113616850A (zh) * | 2021-09-02 | 2021-11-09 | 长春工业大学 | 一种高透明皮肤修复水凝胶敷料及其制备方法 |
| CN113648260A (zh) * | 2021-09-26 | 2021-11-16 | 广东瀚森生物科技有限公司 | 一种酵母修复微精华及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| 何秋星.《化妆品制剂学》.中国医药科学技术出版社,2021,(第1版),第270页. * |
| 俞学锋.《酵母营养的奥秘》.电子科技大学出版社,2017,(第1版),第118-119页. * |
| 彭冠杰等.《美白化妆品科学与技术》.中国轻工业出版社,2019,(第1版),第190-192页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115531601A (zh) | 2022-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104288828B (zh) | 一种医用生物抑瘢除皱敷料及其制备方法 | |
| CN101791283B (zh) | 一种可消除妊娠纹和疤痕的化妆品 | |
| CN103585097A (zh) | 一种白及多糖载表皮生长因子复合物及其制备方法和应用 | |
| CN103006511B (zh) | 水蛭素美白保湿调理霜及其生产工艺 | |
| CN110787100A (zh) | 抗敏舒肤精华液及其制备方法 | |
| CN102266280B (zh) | 精制鹿油在制备保湿化妆品中的应用 | |
| CN104126744A (zh) | 黑枸杞延春美容片 | |
| CN101721347A (zh) | 含人工养殖大鲵组织物或提取液的美容护肤品 | |
| CN110251648A (zh) | 减肥膏及其制备方法 | |
| CN105055849B (zh) | 滋阴养肾的中药提取物及其制备方法和应用 | |
| CN106798915A (zh) | 一种利用rhEGF治疗宫颈糜烂与损伤的凝胶剂及其制备方法 | |
| CN105362410B (zh) | 一种治疗烧烫伤的中药制剂及制备方法 | |
| CN115531601B (zh) | 一种缓解皮肤光电治疗术后炎症反应的水凝胶敷料及其制备方法 | |
| WO2018082117A1 (zh) | 具有祛除皮肤红血丝功能的外用中药组合物及其护肤制剂 | |
| CN105012702A (zh) | 外用生肤油在制备预防或治疗糖尿病性末梢循环障碍及足溃疡的药物中的应用 | |
| CN101132804A (zh) | 治疗皮肤情况，失调或疾病的胚胎皮肤细胞蛋白组合物及其制备和使用方法 | |
| CN106491474A (zh) | 一种利用植物复合肽制备祛痘膏的方法 | |
| CN103875841B (zh) | 一种具有祛除产后妊娠纹功效的茶饮料及其制备方法 | |
| CN102872200A (zh) | 一种治疗斑秃的外用药 | |
| CN102423364A (zh) | 一种治疗面瘫的牵正膏药及其制备方法 | |
| CN104873955A (zh) | 烧伤愈合水凝胶 | |
| CN105213291A (zh) | 一种消除妊娠纹的复合护肤膏及其制备方法 | |
| CN111166849A (zh) | 一种祛除疲劳和改善睡眠的药浴组合物 | |
| CN110934813A (zh) | 一种含脐带血提取物的化妆品组合物及其制备方法 | |
| CN113520991B (zh) | 一种阻断瘢痕形成与逆向修复调节的纳米生物凝胶及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |